The Effects of Low-Dose Growth Hormone in HIV-Infected Men with Fat Accumulation: A Pilot Study

Joan C. Lo,1,2 Kathleen Mulligan,1,2 Mustafa A. Noor,1,3,a Grace A. Lee,1,3 Jean-Marc Schwarz,1,4,a Carl Grunfeld,1,3 and Morris Schambelan1,2

1Department of Medicine, University of California at San Francisco, 2Division of Endocrinology, San Francisco General Hospital, and 3Metabolism and Endocrine Sections, San Francisco Department of Veterans Affairs Medical Center, San Francisco, and 4Department of Nutritional Sciences, University of California at Berkeley, California

Pharmacologic doses of growth hormone (GH) reduce HIV-associated fat accumulation but may worsen glucose metabolism. We investigated the effects of a low dose of GH (1 mg per day) in HIV-infected men with fat accumulation and found that such treatment reduced total fat and increased lean body mass without significant changes in glucose tolerance or insulin sensitivity. Visceral adipose tissue (VAT) levels did not change significantly for the group as a whole, although a reduction in the VAT level was seen in patients with a greater VAT level at baseline.

In the current era of HAART, various syndromes of altered fat distribution, including fat accumulation in the dorsocervical region and abdomen, have been reported in patients with HIV infection [1–3]. For many patients, these body composition changes have adversely affected quality of life [4]. In addition, there are rising concerns that they may be associated with insulin resistance and cardiovascular risk [3, 5, 6].

Previously, we reported that a 6-month course of treatment with a pharmacologic dose of growth hormone (GH) at 3 mg per day reduced total body fat and excess visceral adipose tissue (VAT) in patients with HIV-associated fat accumulation [7]. After an initial worsening in glucose homeostasis, presumably caused by GH-induced hepatic and peripheral insulin resistance, there was subsequent improvement toward pretreatment levels at the end of the study [7, 8]. Other published studies [9, 10], including recently reported data from a large randomized trial of GH therapy [11], confirm the efficacy of pharmacologic GH therapy in reducing total and visceral fat levels (GH dosage, 4–6 mg daily or on alternate days). These studies also suggest the possibility of a dose-response effect with GH [10–11]. Because many patients receiving HAART who experience excess fat accumulation are insulin resistant [3, 6] and thus predisposed to frank diabetes with GH treatment, we thought that it was important to investigate the effectiveness of a lower GH dose in this patient population. The current pilot study was undertaken to determine the metabolic and body composition effects of GH at a dosage of 1 mg per day.

Methods. Five HIV-positive men who had experienced abdominal girth increase and dorsocervical fat pad enlargement while receiving antiretroviral therapy were enrolled in the study. All 5 men had a waist-to-hip ratio >0.95 and a waist circumference >90 cm (table 1). Patients with overt diabetes, abnormal glucose tolerance (2 h–glucose level of >140 mg/dL after a 75-g oral glucose load), fasting triglyceride level >1000 mg/dL, or active malignancies were excluded. The average duration of HIV infection (±SD) was 11 ± 4 years. All patients were receiving a stable antiretroviral regimen that they continued to receive during the study (table 1). None had received systemic glucocorticoids or megestrol acetate in the previous 5 years. The study was approved by the Committee on Human Research at the University of California, San Francisco, and written consent was obtained from each subject before enrollment.

Subjects were admitted to the General Clinical Research Center at San Francisco General Hospital and were placed on a diet with fixed nutrient proportions, as described elsewhere [7]. Subjects underwent a 5-day inpatient metabolic study that included total and regional body composition studies, fasting lipid level measurements, an oral glucose tolerance test, and a euglycemic hyperinsulinemic clamp. Thereafter, subjects began treatment with GH (Serono Laboratories) at 1 mg per day (11–14 µg/kg per day) by subcutaneous injection. The same 5-day metabolic ward assessments were performed at month 1 and month 6 of GH therapy.

Weight, height, and anthropometric measurements were performed as described elsewhere [7], including buffalo hump size, which was measured as length times width along surface contours. Fat and lean body mass (LBM) were measured by dual-energy x-ray absorptiometry (Lunar model DPX), with manual analyses of regional fat [1, 7]. Abdominal adipose tissue was measured by CT using a HiSpeed CT/i Scanner (GE Medical Systems).
Table 1. Baseline characteristics of subjects in a pilot study of the effects of low-dose growth hormone in HIV-infected men with fat accumulation.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, years</th>
<th>BMI</th>
<th>Waist circumference, cm</th>
<th>Waist-to-hip ratio</th>
<th>CD4⁺ cell count, cells/μL</th>
<th>Antiretroviral regimen(b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>48</td>
<td>25.7</td>
<td>93.0</td>
<td>0.98</td>
<td>412</td>
<td>D4T, 3TC, IDV, RTV</td>
</tr>
<tr>
<td>2</td>
<td>49</td>
<td>23.8</td>
<td>92.5</td>
<td>0.98</td>
<td>449</td>
<td>RTV, AMP, EFV</td>
</tr>
<tr>
<td>3</td>
<td>46</td>
<td>28.0</td>
<td>94.5</td>
<td>1.00</td>
<td>527</td>
<td>DDI, 3TC, NEV</td>
</tr>
<tr>
<td>4</td>
<td>58</td>
<td>26.1</td>
<td>102.5</td>
<td>1.04</td>
<td>1433</td>
<td>3TC, IDV, EFV</td>
</tr>
<tr>
<td>5</td>
<td>41</td>
<td>29.8</td>
<td>102.2</td>
<td>1.02</td>
<td>464</td>
<td>AZT, 3TC, RTV/LPV</td>
</tr>
</tbody>
</table>

\(b\) All patients received the same antiretroviral regimen for \(\geq6\) months prior to the study, with the exception of patient 2, who underwent a transient (<1 month) substitution of delavirdine for RTV 2 months before the study but then returned to his stable regimen of RTV, AMP, and EFV, which he had been receiving for the previous year. Patient 2 was also receiving human chorionic gonadotropin (for Kaposi sarcoma in remission) and atorvastatin, and patient 3 was receiving testosterone (replacement), gemfibrozil, and niacin during the study.

NOTE. All patients had experienced both enlargement of the dorsocervical fat pad and an increase in abdominal girth; in addition, patients 1, 2, and 4 also complained of loss of fat in the face and extremities. AMP, amprenavir; AZT, zidovudine; BMI, body mass index (calculated as weight [in kg] divided by height [in m] squared); DDI, didanosine; D4T, stavudine; EFV, efavirenz; IDV, indinavir; LPV, lopinavir; NEV, nevirapine; RTV, ritonavir; 3TC, lamivudine.

Results. Overall, GH was well tolerated, with the most-common complaints being very mild arthralgias (in 2 patients) and nonpitting edema in the extremities (in 1 patient) that improved over the course of the study. However, patient 3 developed carpal tunnel syndrome; the dose of GH was reduced to 0.5 mg per day for 2 weeks and was then discontinued at month 4 of therapy. His final study measurements were performed just prior to discontinuation.

Total body fat and trunk fat decreased and lean body mass increased in all subjects (table 2). There were no significant changes in appendicular fat or body weight. Three patients experienced a reduction in VAT of 14%–54% (figure 1), whereas 2 patients experienced an increase in VAT of 7%–10%; for the group as a whole, there were no significant changes in VAT, abdominal SAT, waist circumference, or waist-to-hip ratio. All patients had a reduction in buffalo hump size ranging from 13% to 89% (median reduction, 56%).

IGF-1 levels increased significantly at both month 1 (315 ± 73 ng/mL; \(P < .001\)) and month 6 of therapy (353 ± 133 ng/mL; \(P < .001\)), compared with baseline (142 ± 67 ng/mL). During the 6 months of treatment, there were no significant changes in fasting free fatty acid levels; triglyceride levels; total, high-density lipoprotein cholesterol levels; and calculated low-density lipoprotein cholesterol levels; nor were there significant changes in fasting glucose levels or HgA1C. Although a trend to transient worsening in glucose tolerance was noted in 4 patients (followed by improvement towards baseline in 3 patients), overall differences were not significant (glucose AUC, 431 ± 15, 464 ± 47, and 438 ± 47 mg × h/dL at baseline, month 1, and month 6, respectively; \(P = .30\)). There was also no significant change in insulin sensitivity, as measured by the euglycemic hyperinsulinemic clamp (M/I, 4.97 ± 3.35, 3.52 ± 2.84, and 4.43 ± 1.73 mg/kgLBM × min/μUINSULIN/mL [×100], respectively; \(P = .44\)).
Table 2. Body composition during growth hormone treatment in a pilot study of the effects of low-dose growth hormone in HIV-infected men with fat accumulation.

<table>
<thead>
<tr>
<th>Method, measure</th>
<th>Baseline</th>
<th>Month 1 of therapy</th>
<th>Month 6 of therapy</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dual energy x-ray absorptiometry, mean kg ± SD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total body fat</td>
<td>19.0 ± 3.9</td>
<td>17.5 ± 3.2</td>
<td>16.3 ± 4.8</td>
<td>.04</td>
</tr>
<tr>
<td>Trunk fat</td>
<td>12.9 ± 2.0</td>
<td>11.8 ± 2.1</td>
<td>10.7 ± 2.9</td>
<td>.04</td>
</tr>
<tr>
<td>Appendicular fat</td>
<td>5.2 ± 1.6</td>
<td>4.8 ± 0.9</td>
<td>4.8 ± 1.6</td>
<td>.42</td>
</tr>
<tr>
<td>Lean body mass</td>
<td>59.8 ± 4.2</td>
<td>61.1 ± 4.8</td>
<td>63.6 ± 5.4</td>
<td>.008</td>
</tr>
<tr>
<td>Abdominal CT, mean cm² ± SD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visceral fat</td>
<td>197.7 ± 107.0</td>
<td>...</td>
<td>162.0 ± 83.7</td>
<td>.20</td>
</tr>
<tr>
<td>Subcutaneous fat</td>
<td>185.0 ± 14.8</td>
<td>...</td>
<td>170.6 ± 44.1</td>
<td>.38</td>
</tr>
</tbody>
</table>

a P values were obtained using repeated measures analysis of variance for values (for fat and lean body mass) at baseline, month 1, and month 6 of therapy and paired t test for values (visceral and subcutaneous fat area) at baseline and month 6 of therapy.

b Compared with baseline, by Student-Newman-Keuls test.

Resting energy expenditure was unchanged during GH treatment (37.4 ± 1.0, 38.0 ± 2.3, and 37.3 ± 1.8 kcal/kg LBM per day at baseline, month 1, and month 6, respectively; P = .57). There were trends to increased fasting lipid oxidation (1.34 ± 0.23, 1.49 ± 0.20, and 1.56 ± 0.12 mg/kg LBM/min, respectively; P = .065) and decreased carbohydrate oxidation (2.34 ± 0.55, 2.17 ± 0.66, and 1.89 ± 0.31 mg/kg LBM/min, respectively; P = .09).

Neither resting energy expenditure nor substrate oxidation rates measured during hyperinsulinemia changed with GH treatment.

**Discussion.** These results indicate that even at a dosage as low as 1 mg per day, GH reduces total body fat and trunk fat and increases LBM in HIV-infected men with fat accumulation. The average magnitude of fat loss was slightly more than one-half that seen in our previous study of GH at 3 mg per day [7], consistent with more modest effects of the lower dose on lipid oxidation. In the present study, lipid oxidation increased by only 16%, whereas it increased by 84% in patients treated with GH at 3 mg per day (P < .001) [8].

It is interesting that, in both this and our former study [7], patients who lost VAT during GH treatment had the largest amount of VAT at baseline (figure 1). Thus, it is possible that the level of baseline VAT is a factor in determining the amount of VAT reduction with GH. The broad range of intra-abdominal fat content, despite a waist-to-hip ratio > 0.95 and a waist circumference > 90 cm, may have contributed to the variable response of VAT to GH in these patients. Future studies should consider whether there are additional anthropometric criteria to better identify patients with increased VAT (or perhaps excess VAT should be used as an entry criterion), because these individuals may benefit most from GH therapy. In addition, the optimal dose and duration of treatment needs to be determined. For example, in HIV-seronegative men with abdominal obesity, an even lower dosage of GH (e.g., 9.5 μg/kg per day) over a longer treatment period was effective in reducing visceral adiposity and in improving glucose and lipid metabolism [14].

Changes in appendicular fat were not observed in this study, nor were they observed in our prior pilot study [7], although further loss of subcutaneous fat with GH treatment is a potential concern in patients with peripheral lipoatrophy. Other studies have shown that appendicular fat stores may be reduced.

![Figure 1](https://academic.oup.com/cid/article-abstract/39/5/732/364208)
with GH treatment [10, 15], and it is possible that a similar effect will be evident after a longer period of GH treatment, despite the lower dose.

In contrast to a dosage of 3 mg per day, the effects of GH at 1 mg per day on glucose metabolism, as measured by fasting glucose, oral glucose tolerance, and insulin-mediated glucose uptake, were more modest and not statistically significant. Although we observed a lower increment in IGF-1 with a 1-mg-per-day dosage of GH, compared with a 3-mg-per-day dosage, IGF-1 levels reached the supraphysiologic range for 3 patients, and 1 patient developed carpal tunnel syndrome, requiring treatment cessation. Thus, prolonged GH treatment, even at this lower dosage, should be considered cautiously, given the adverse consequences of long-term GH excess.

In summary, the results of this pilot study suggest that treatment with GH at a dose of 1 mg per day reduces total body fat and increases LBM without significant adverse effects on glucose metabolism. These results need to be confirmed in a larger randomized study. Additional studies are also needed to determine whether this dose of GH is effective in reducing VAT, particularly in patients with documented high visceral fat content.

Acknowledgments

We thank the San Francisco General Hospital (SFGH) General Clinic Research Center Nursing and Dietary staff, the SFGH Department of Radiology, B. Chang, J. Hirai, C. Yee-Hicaiji, J. Shigenaga, V. Tai, L. Alvarez, and G. Del Puerto, for their help in performing this study, and Serono Laboratories, for their provision of growth hormone.

Financial support. The National Institutes of Health (grants DK45833 and DK54615) and a Clinical Associate Physician Award from the National Center for Research Resources, National Institutes of Health (grant RR00083).

Conflict of interest. J.C.L., K.M., C.G., and M.S. have received research support and/or funding from Serono Laboratories. In addition, Serono Laboratories provided the growth hormone used in this and other studies performed by these investigators. All other authors: No conflict.

References


